- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia
- Interventions
- Obicetrapib, Ezetimibe 10mg, Obicetrapib placebo, Ezetimibe placebo
- Drug · Other
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Northridge, California • Ocala, Florida + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hypercholesterolemia
- Interventions
- Inclisiran, Ezetimibe, Matching Placebo for Inclisiran, Matching Placebo for Ezetimibe
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Dothan, Alabama • DeLand, Florida + 19 more
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia
- Interventions
- Obicetrapib 5mg, Ezetimibe 10mg, Placebo
- Drug · Other
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 3
- States / cities
- Lincoln, California • Evanston, Illinois • Houston, Texas
- Conditions
- Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease, Atherosclerosis, Myocardial Infarction
- Interventions
- Extended release niacin, Simvastatin
- Drug
- Lead sponsor
- Axio Research. LLC
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 3,414 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Pheonix, Arizona + 52 more
- Conditions
- Cholesterol, LDL
- Interventions
- Ezetimibe and Simvastatin
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 20 Years to 70 Years · Male only
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hypercholesterolemia
- Interventions
- BMS-201038 (AEGR-733), Ezetimibe
- Drug
- Lead sponsor
- Aegerion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
- Interventions
- obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg, Placebo
- Drug · Other
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 20
- States / cities
- Sun City West, Arizona • La Jolla, California • Jacksonville, Florida + 16 more
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe
- Biological · Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 615 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 40 more
- Conditions
- Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
- Interventions
- Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe, Combination Therapy placebo, Obicetrapib Placebo, Ezetimibe Placebo
- Combination Product · Drug · Other
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 45
- States / cities
- Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more